MedTrace Logo

Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant

NCT03649074 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2023-08-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effects of combining AKL-T01 (with AKL-X01 symptom tracking) as adjunctive treatment to stimulant medication, and to understand the effects of AKL-T01 treatment (with AKL-X01 symptom tracking) in participants not recently on medication.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DEVICE

AKL-T01

AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor "driving" task.

Sponsors & Collaborators

  • Akili Interactive Labs, Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel Lazkowitz, MD, PhD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-28
Primary Completion
2019-09-23
Completion
2019-09-23
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03649074 on ClinicalTrials.gov